Table 1.
Molecular Abnormalities Detected in AUS/FLUS FNA Samples and Associated Cancer Risk
| Number of mutation-positive samples | Nodules with surgical outcome | Cancer on surgery (cancer risk) | |
|---|---|---|---|
| Point mutation | |||
| NRAS | 7 | 5 | 3 (60%) |
| HRAS | 7 | 6 | 5 (83%) |
| KRAS | 3 | 3 | 3 (100%) |
| PTEN | 2 | 1 | 0 |
| EIF1AX | 2 | 2 | 1 (50%) |
| BRAFV600E | 1 | 1 | 1 (100%) |
| BRAFK601E | 1 | 1 | 1 (100%) |
| TSHR | 1 | 0 | 0 |
| Gene fusions | |||
| THADA | 3 | 3 | 2 (67%) |
| PPARG | 1 | 1 | 1 (100%) |
| NTRK3 | 1 | 1 | 1 (100%) |
| NTRK1 | 1 | 1 | 1 (100%) |
| ALK | 1 | 1 | 1 (100%) |
AUS/FLUS, atypia of undetermined significance/follicular lesion of undermined significance; FNA, fine-needle aspiration.